Developing-potential-treatment-for-severe-COVID19-complications
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory complications for which very limited treatment options are currently available.This new therapeutic option could help the 67-85% of COVID-19 patients admitted to the intensive care unit who suffer from acute respiratory distress syndrome,1 potentially reducing the need for mechanical ventilation and potentially saving lives.The initiation of this Phase 2 tri...
Source: Boehringer Ingelheim Corporate News - October 28, 2020 Category: Research Source Type: news

Boehringer Ingelheim Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigsThis novel device will bring benefits to swine producers ensuring improved safety and efficacy of vaccinationForming new partnerships is fully aligned with part of Boehringer Ingelheim ’s animal health strategy, aiming to accelerate innovation and growth (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 23, 2020 Category: Research Source Type: news

Purevax range now available in 0.5 ml presentation
Purevax ® range now available in 0.5 ml presentationBoehringer Ingelheim announces reduced volume vaccines for catsMore convenient vaccination experience combined with same efficacyPurevax ® is the only fully adjuvant‑free feline vaccine range (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 14, 2020 Category: Research Source Type: news

Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the ClinicThe collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim ’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by Oxford BioTherapeutics’ proprietary OGAP® (Oxford Genome Anatomy Project) target discovery platform, is the latest in a series of collaborations that strengthens Boehringer Ingelheim’s position and leading asse ts in cancer immunology.  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 14, 2020 Category: Research Source Type: news

Advance study shows vaccinating results in increased milk production
New ADVANCE study shows vaccinating results in increased milk productionThe ADVANCE1 study demonstrates benefits of vaccinationBoehringer Ingelheim remains committed to bringing new findings to its customers through continuous research (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 5, 2020 Category: Research Source Type: news

Winners of the 2020 European PRRS Research Award
announcedBoehringer Ingelheim recognizes scientific excellence by awarding three research proposals with a funding of 25,000 euro eachThe company sponsored the annual European PRRS Awards for the seventh time (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 1, 2020 Category: Research Source Type: news

Boehringer Ingelheim and Fraunhofer partnership
Boehringer Ingelheim and Fraunhofer IME launch collaborationThis partnership aims to develop sustainable animal health productsBoehringer Ingelheim continues to strive to minimize the environmental footprint of its operations and products (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 30, 2020 Category: Research Source Type: news

Partnership to further develop pet market in China
Boehringer  Ingelheim invests to further develop the pet care market in ChinaBoehringer  Ingelheim has acquired an equity stake in New Ruipeng Group (NRP Group) which operates digital and clinical pet services across China The  partnership with NRP Group aims to expand health solutions, quality advice and professional care to the growing number of pets and pet owners in China  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 29, 2020 Category: Research Source Type: news

World Rabies Day 2020 sustainable dog vaccination
Boehringer Ingelheim steps up its efforts to eliminate rabies through sustainable programs  Vaccinating dogs most effective to protect human lives  Boehringer Ingelheim supports local self-sustaining programs that fight rabies  Contributing to continuous rabies awareness and vaccination campaigns key to the company ’s strategy  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 28, 2020 Category: Research Source Type: news

clinical_collaboration_with_Mirati
BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR  First clinical study to evaluate novel combination blocking KRAS G12C and its activator SOS1 to potentially increase the therapeutic benefit for lung and colorectal cancer patientsStudy is based on preclinical evidence suggesting synergistic effect of KRAS G12C and SOS1 inhibition (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 17, 2020 Category: Research Source Type: news

digital_leader_award_2020
Successful IT transformation recognized: Boehringer Ingelheim wins Digital Leader Award 2020Award values strategic contribution of the IT organization to the innovative strength of the pharmaceutical companyTransformation drives company-wide digital innovationEarly investments in digital technologies have been crucial to maintain business operations under COVID-19     (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2020 Category: Research Source Type: news

Phase II results cognitive impairment schizophrenia
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophreniaResults presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 has met its primary endpoint1,2Trial results, together with an ongoing combination Phase II study of BI 425809 and adjunctive computerized cognitive training, add to the body of evidence for Boehringer Ingelheim ’s schizophrenia research program3Cognitive impairment associated with schizophrenia (CIAS) has a significant negative impact on daily functioning and remains a focus for Boehringer I...
Source: Boehringer Ingelheim Corporate News - September 14, 2020 Category: Research Source Type: news

Partnership-with-clicktherapeutics
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia This collaboration combines Click Therapeutics ’ specialty in developing efficacious and engaging digital therapeutics with Boehringer Ingelheim’s expertise in clinical development of treatments for neuropsychiatric diseases, furthering Boehringer Ingelheim’s commitment to exploring digital innovations to benefit patients with unmet medica l needsTogether the companies will develop and commercialize a prescription-b...
Source: Boehringer Ingelheim Corporate News - September 11, 2020 Category: Research Source Type: news

Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal CancersFirst-in-class bi-specific antibody BI 905711 activates a pathway in TRAILR2 and CDH17 co-expressing tumor cells that leads to their destructionMay result in a more tolerable and selective therapy for patients affected with gastrointestinal cancers by avoiding liver toxicity commonly observed in other therapy approaches targeting TRAILR2Adds a promising candidate to Boehringer Ingelheim ’s multipronged oncology portfolio that combines cancer cell-directed and cancer immunol...
Source: Boehringer Ingelheim Corporate News - September 10, 2020 Category: Research Source Type: news

discontinuation-bi-1467335-diabetic-retinopathy
Boehringer Ingelheim discontinues development of BI 1467335 for Diabetic RetinopathyBI 1467335 was acquired from Pharmaxis in 2015 as part of Boehringer Ingelheim ’s growing Retinal Health R&D pipeline portfolioBoehringer Ingelheim has terminated the agreement with Pharmaxis with 90 days ’ notice during which time Pharmaxis can request return of all existing data and intellectual property.Boehringer Ingelheim will continue to advance its comprehensive portfolio of next generation retinal therapy approachesPharmaxis will continue its development of small molecule amine oxidase inhibitors with a phase 2 study...
Source: Boehringer Ingelheim Corporate News - September 7, 2020 Category: Research Source Type: news

GioTag Final Data
Conclusions from the observational GioTag study were   published in Future OncologyiGiotrif/Gilotrif (afatinib) followed by osimertinib showed median overall survival (OS) of 37.6 months in patients with EGFR mutation-positive NSCLC (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 2, 2020 Category: Research Source Type: news

Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 27, 2020 Category: Research Source Type: news

Launch-of-CARE-Consortium
Europe ’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus ThreatsCARE (Corona Accelerated R&D in Europe), supported by Europe ’s Innovative Medicines Initiative (IMI), is the largest undertaking of its kind dedicated to discovering and developing urgently needed treatment options for COVID-19The initiative is committed to a long-term understanding of the disease and development of therapies for COVID-19 and future coronavirus threats in addition to urgent efforts to repurpose existing therapies as potential immediate response.The CARE consortium will acceler...
Source: Boehringer Ingelheim Corporate News - August 18, 2020 Category: Research Source Type: news

biolabs-heidelberg
Boehringer Ingelheim Supports BioLabs First European Location BioLabs Heidelberg with Founding Sponsorship   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 17, 2020 Category: Research Source Type: news

InPedILD_trial_enrollment
Phase III InPedILD ™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung diseaseFirst-of-its-kind clinical trial in children and adolescents with fibrosing interstitial lung disease (ILD) initiated globallyThis new study builds on the Phase III INBUILD ® trial and approval of Ofev® in adult patients with fibrosing ILDs with a progressive phenotype1,2,3Global Phase III multicentre clinical trial is planned to be conducted in approximately 70 sites in 24 countries (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 12, 2020 Category: Research Source Type: news

Fight against COVID-19 pandemic shapes global business activities
First half 2020: Fight against COVID-19 pandemic shapes global business activities of Boehringer IngelheimCompany engaged in various initiatives to contain and cope with the global spread of COVID-19Protection of employees and safeguarding of worldwide pharmaceutical supply prioritiesNet sales growth under difficult market conditions – company expects market volatility to remain intense (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 3, 2020 Category: Research Source Type: news

emperor-reduced-heart-failure-toplineresults
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetesEmpagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction  Treatment of heart failure is an important unmet need with over half of those diagnosed dying within five years1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 30, 2020 Category: Research Source Type: news

Boehringer Ingelheim acquires Global Stem cell Technology
Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal HealthBoehringer Ingelheim joins forces with Belgian biotech company GST which develops and produces state-of-the art stem cell products for horses and petsThe acquisition follows two years of successful partnership that brought the first-ever registered stem cell-based veterinary medicine to the European marketDecision to acquire GST is fully aligned with part of Boehringer Ingelheim ’s Animal Health strategy, aiming to strengthen its portfolio capabilities to accelerate innovation and growth (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 27, 2020 Category: Research Source Type: news

EC_approval_nintedanib_ILD_PF
European Commission approves third nintedanib indication in pulmonary fibrosis1The approval is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1The decision is based on the results of the INBUILD ® trial, the first study to evaluate patients with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behavior.2Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated inters...
Source: Boehringer Ingelheim Corporate News - July 15, 2020 Category: Research Source Type: news

Perceived burden of COPD is higher for younger patients
Perceived burden of disease is greater in younger people living with COPD, global survey revealsCOPD impacts younger patients ’ daily activities more significantlyYounger patients feel more negative about their diseaseYounger patients want and need more support from HCPs to achieve optimal treatment management    (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 9, 2020 Category: Research Source Type: news

AMR_Action_Fund
Fighting antibiotic resistance: Boehringer Ingelheim joins AMR Action FundCompany contributes USD 50 million to invest in antibiotic R&D within AMR Action FundAntimicrobial resistance (AMR) considered one of the most urgent global medical challengesJoint approach to combat the global threat of AMR  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 9, 2020 Category: Research Source Type: news

Numab
Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal DiseasesThe collaboration with Numab Therapeutics expands Boehringer Ingelheim ’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA)Numab ’s proprietary platform enables the engineering of first-in-class and best-in-class bi- and multi-specific antibodies in a true plug-and-play fashion (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 7, 2020 Category: Research Source Type: news

ExternalInnovationHubChina
Boehringer Ingelheim Launches External Innovation Hub in China  Boehringer Ingelheim is increasing its efforts to access external innovation in China, recognizing the opportunities offered by the prospering Chinese life science ecosystem, to develop new breakthrough medicines for patients with high unmet medical needsThe External Innovation Hub China formalizes these efforts by co-locating business leaders from Boehringer Ingelheim ’s partnering functions to facilitate access to a range of collaboration opportunities. Academic and biotech institutions will also have access to the Boehringer Ingelheim Venture Fun...
Source: Boehringer Ingelheim Corporate News - July 2, 2020 Category: Research Source Type: news

CAROLINA-CARMELINA-Asia-analysis
Cardiovascular and renal safety profile of linagliptin demonstrated in Asian adults with type 2 diabetesIn a sub-analysis of the CAROLINA ® cardiovascular outcome trial, linagliptin demonstrated no increased cardiovascular risk versus glimepiride in Asian adults with type 2 diabetes and high cardiovascular risk1In addition, a sub-analysis of the CARMELINA ® cardiovascular outcome trial demonstrated a similar cardiovascular and renal safety profile for linagliptin versus placebo in Asian adults with type 2 diabetes and high cardiorenal risk2  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 29, 2020 Category: Research Source Type: news

Classical Swine Fever live vaccine approved in China
Boehringer Ingelheim ’s China-developed Classical Swine Fever live vaccine approvedBoehringer Ingelheim received a marketing authorization for Ingelvac ® CSF MLV, the first classical Swine Fever live vaccine jointly developed by a multinational company and Chinese research institutesThe company reaffirms its commitment to supplying innovative swine vaccines for the Chinese industry (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 25, 2020 Category: Research Source Type: news

EUbOPEN
New consortium EUbOPEN will provide tools to unlock disease biology66 million euros to generate open-access chemical tools   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 8, 2020 Category: Research Source Type: news

LastMile – improving through digital
“LastMile” – improving through digitalWith the new mobile app, the “LastMile” team can now better manage day-to-day activities and support farmers, retailers and veterinarians more effectively (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 4, 2020 Category: Research Source Type: news

CHMP_opinion_nintedanib_ILD_PF
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis1The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).2The U.S. Food and Drug Administration (FDA) and Health Canada recently approved nintedanib as the first treatment for the same patient population.3,4Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in mo...
Source: Boehringer Ingelheim Corporate News - May 29, 2020 Category: Research Source Type: news

DCRI-collaboration-empact-mi
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin ’s effects following an acute myocardial infarction Ischemic heart disease, including myocardial infarction, is the leading cause of death in the world1EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetesThe trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the li...
Source: Boehringer Ingelheim Corporate News - May 26, 2020 Category: Research Source Type: news

Winners of 2020 BVDzero Case Awards
announcedBoehringer Ingelheim grants a total prize of 15,000 euros to the top 10 clinical casesThe company encourages the search for both clinical and subclinical cases of bovine viral diarrhea (BVD) in cattle herds, aiming to improve BVD awareness (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 25, 2020 Category: Research Source Type: news

AcquisitionOfNorthernBiologics
Boehringer Ingelheim Acquires Northern Biologics ’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio Acquisition provides assets targeting the tumor stroma and myeloid cellsThese new programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim ’s position in cancer immunology, with leading assets and robust capabilities in cancer vaccines, oncolytic viruses,  T-cell engagers and myeloid cell modulators Acquisition of Versant-built company based in Toronto ’s MaRS Discovery D...
Source: Boehringer Ingelheim Corporate News - May 14, 2020 Category: Research Source Type: news

GeographicAtrophyCollabortationWithCDR-Life
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness WorldwideThe collaboration with CDR-Life is the second strategic partnership within a year for Boehringer Ingelheim in retinal diseases, furthering the company ’s commitment to develop novel treatments and technologies for patients who have only inadequate treatment options Together the partners will advance CDR-Life ’s preclinical antibody fragments targeting a key pathway in geographic atrophy (GA)  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 13, 2020 Category: Research Source Type: news

European_Commission_approves_nintedanibSSc-ILD
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)Approval is based on the SENSCIS ® study which showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD)1Following the FDA ’s approval in September 2019, nintedanib in SSc-ILD has so far been approved in 15 countries including Canada, Japan and BrazilBeing the first and only approved treatment option available for people living with SSc-ILD, the approval constitutes a breakthrough in an area of high unmet need (Source: Boehring...
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news

PatientView survey
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey Boehringer Ingelheim among top ten most “patient-centric” pharma companies* (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news

Aservo EquiHaler wins Red Dot 2020 for design quality
Aservo ® EquiHaler® wins Red Dot for outstanding design qualityBoehringer Ingelheim ’s Aservo® EquiHaler® wins the Red Dot Award: Product Design 2020Red Dot has become established internationally as one of the most sought-after seals of quality for excellent design (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news

2020 European PRRS Research Award sponsorship
2020 European PRRS Research Award: Boehringer Ingelheim calls for submissionsBoehringer Ingelheim funds three research projects for improved control of swine disease PRRS with a total of 75,000 eurosThis Award aims at encouraging research and enhancing the interaction among swine researchers and veterinarians (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 14, 2020 Category: Research Source Type: news

FOYA_Shanghai
Boehringer Ingelheim Biopharmaceuticals China receives “Facility of the Year” AwardBoehringer Ingelheim ’s commercial manufacturing site OASIS in Shanghai has been honored with an award in the ‘Facility of the Year’ programThe International Society for Pharmaceutical Engineering has awarded the company the prize with an'Honorable Mention 'The facility impresses with its flexible and well thought-out concept (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 9, 2020 Category: Research Source Type: news

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Solid performance in previous years strengthened the basis for absorbing the effects of COVID-19 spreading; production continues at a high levelStrong development pipeline; 18.2% of net sales invested in R&DGlobal Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 8, 2020 Category: Research Source Type: news

Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support ProgramGlobal support fund for local relief increased to EUR 5.8 millionOver 100 scientists and 11,000 lab hours committed to COVID-19 research in international consortia, expected to expand10 days paid leave offered to 51,000 employees for volunteeringEUR 580,000 relief fund made available for Making More Health communities and social entrepreneurs in India and Kenya (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 8, 2020 Category: Research Source Type: news

BI_X_Shanghai
Boehringer Ingelheim opens second branch of digital lab BI X in ShanghaiInitial investment of 3 million euros for tailored digital solutions focusing Chinese patients and customers20 new jobs for digital talents  Close collaboration between BI X China and BI X GermanyBoehringer Ingelheim is among the first wave of pharmaceutical companies to build a dedicated digital innovation business in China (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 30, 2020 Category: Research Source Type: news

Fda-crl-t1d
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2020 Category: Research Source Type: news

Uncommon_Mutations_Database
New uncommon EGFR mutations database published featuring clinical outcomes of NSCLC patients treated with afatinib  New searchable database of published clinical outcomes from patients with uncommon EGFR mutations in advanced/metastatic NSCLC treated with afatinib, reported by individual mutation, is available for global clinician use at:www.uncommonEGFRmutations.comPooled analysis of 693 NSCLC patient cases published in the Journal of Thoracic Oncology (JTO) supports the use of afatinib against the most prevalent uncommon EGFR mutations (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 16, 2020 Category: Research Source Type: news

Boehringer Ingelheim Ruminant Well-Being Awards 2020
The World Association for Buiatrics and Boehringer Ingelheim announce the'Ruminant Well-Being Awards ’Boehringer Ingelheim demonstrates the long-term commitment for animal well-being by supporting these biennial awardsThe winner in each of the two awards will receive 10,000 euro (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 16, 2020 Category: Research Source Type: news

FDA-Fast-Track-chronic-kidney-disease
U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 12, 2020 Category: Research Source Type: news

CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease  Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults1Based upon positive SENSCIS ® trial results nintedanib was approved as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with SSc-ILD2Nintedanib is already approved in more than 70 countries for the tre...
Source: Boehringer Ingelheim Corporate News - February 28, 2020 Category: Research Source Type: news